<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507607</url>
  </required_header>
  <id_info>
    <org_study_id>0237801</org_study_id>
    <nct_id>NCT04507607</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection</brief_title>
  <official_title>Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness of mother-to-child block of CHB in pregnant women in the middle and later&#xD;
      stages of pregnancy has been recognized by the guidelines. TAF, as a newly marketed antiviral&#xD;
      drug, has not been conclusively concluded in terms of its efficacy and postpartum safety in&#xD;
      preventing mother-to-child transmission in pregnant women.Our purpose is to explore the TAF&#xD;
      for CHB the curative effect of pregnant and postnatal security.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diagnosis at the infection clinic of the Third Affiliated Hospital of Sun Yat-sen&#xD;
      University, the eligible patients were enrolled into the group.Each person will sign the&#xD;
      informed consent prior to enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver indicators of intrapartum</measure>
    <time_frame>intrapartum</time_frame>
    <description>The level of liver function (ALT、AST)、HBV DNA、HBV Serological markers (HBsAg、HBeAg、HBeAb) in pregnant women at birth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver indicators of postpartum</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>The level of liver function (ALT、AST)、HBV DNA、HBV Serological markers (HBsAg、HBeAg、HBeAb) in pregnant women 1 month、3 month、7 month、9 month、12 month after delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver indicators of pregnancy</measure>
    <time_frame>24 weeks gestation until delivery</time_frame>
    <description>The level of liver function (ALT、AST)、HBV DNA、HBV Serological markers (HBsAg、HBeAg、HBeAb) in pregnant women taking TAF 0、4、8、12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Mother-to-child Block</condition>
  <condition>Antiviral Treatment</condition>
  <arm_group>
    <arm_group_label>Pregnant women with CHB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>women with CHB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide 25 MG</intervention_name>
    <description>TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.</description>
    <arm_group_label>Pregnant women with CHB</arm_group_label>
    <arm_group_label>women with CHB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  25 pregnant women with HBeAg (+), HBV DNA ≥ 2*10^6IU/mL who met the diagnostic&#xD;
             criteria in the guidelines for the prevention and treatment of chronic hepatitis B&#xD;
             were pregnant women at 24-28 weeks of pregnancy.&#xD;
&#xD;
          -  25 non-pregnant women with HBeAg (+), HBV DNA ≥ 2*10^6IU/mL who met the diagnostic&#xD;
             criteria in the guidelines for the prevention and treatment of chronic hepatitis B.&#xD;
&#xD;
          -  The enrolled patients were all newly admitted patients without treatment, and if they&#xD;
             did not meet the standard after completing the relevant examination, they would be&#xD;
             removed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coinfection with HAV, HCV, HDV, HEV or HIV;&#xD;
&#xD;
          -  A history of antiviral therapy or concurrent treatment with immunoregulatory drugs,&#xD;
             antitumor drugs, cytotoxic drugs or immunosuppressive steroids;&#xD;
&#xD;
          -  Three-dimensional ultrasonography showed fetal malformation;&#xD;
&#xD;
          -  The spouse is infected with HBV;&#xD;
&#xD;
          -  History of decompensated liver disease (e.g., decompensated liver disease with&#xD;
             coagulation disorders, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia,&#xD;
             ascites and esophageal varicose bleeding), history of liver cancer or other chronic&#xD;
             liver disease (e.g., autoimmune hepatitis) or clinical symptoms;&#xD;
&#xD;
          -  History of immune diseases;&#xD;
&#xD;
          -  A history of serious cardiovascular disease;&#xD;
&#xD;
          -  Other reasons the researchers considered it inappropriate to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LinChaoshuang</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LiXin Xiao</last_name>
      <phone>18613016355</phone>
      <email>amia1995@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Chaoshuang Lin</investigator_full_name>
    <investigator_title>Professor Lin</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

